We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

81 hedge funds and large institutions have $164M invested in Protagonist Therapeutics in 2019 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 15

38% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 13

13.19% more ownership

Funds ownership: 72.06% → 85.25% (+13%)

7% more funds holding

Funds holding: 76 → 81 (+5)

28% less capital invested

Capital invested by funds: $228M → $164M (-$64M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
81
Holders Change
+5
Holders Change %
+6.58%
% of All Funds
1.6%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
18
Increased
34
Reduced
15
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$16.9M
2
SFM
Sphera Funds Management
Israel
+$6.26M
3
BlackRock
BlackRock
New York
+$4.75M
4
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
+$2.48M
5
O
OrbiMed
New York
+$1.9M

Top Sellers

Rank Fund Capital Flow
1
VMI
VHCP Management III
New York
-$9.85M
2
ACP
Acuta Capital Partners
California
-$5.03M
3
VMI
VHCP Management II
New York
-$3.92M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.95M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.89M
Name Holding Trade Value Shares
Change 		Change in
Stake
KWMG
51
King Wealth Management Group
Florida
$155K +$49.7K +5,000 +29%
UBS Group
52
UBS Group
Switzerland
$149K +$45.1K +4,540 +27%
Goldman Sachs
53
Goldman Sachs
New York
$142K -$1.36M -136,822 -87%
Grantham, Mayo, Van Otterloo & Co (GMO)
54
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$141K -$183K -18,400 -48%
Arrowstreet Capital
55
Arrowstreet Capital
Massachusetts
$141K +$199K +20,000 New
Barclays
56
Barclays
United Kingdom
$130K +$39.3K +3,956 +27%
PPA
57
Parametric Portfolio Associates
Washington
$128K +$6.39K +644 +4%
SO
58
STRS Ohio
Ohio
$124K +$175K +17,600 New
FIM
59
Freedom Investment Management
Connecticut
$119K -$15.5K -1,564 -8%
RhumbLine Advisers
60
RhumbLine Advisers
Massachusetts
$115K +$7.46K +751 +5%
New York State Common Retirement Fund
61
New York State Common Retirement Fund
New York
$109K – – –
BFM
62
Boothbay Fund Management
New York
$91K -$358K -36,079 -74%
AllianceBernstein
63
AllianceBernstein
Tennessee
$89K – – –
JG
64
Jefferies Group
New York
$83K +$117K +11,756 New
Manulife (Manufacturers Life Insurance)
65
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$79K +$2.08K +210 +2%
AIG
66
American International Group
New York
$78K +$2.84K +286 +3%
Bank of America
67
Bank of America
North Carolina
$52K -$24K -2,413 -25%
Citigroup
68
Citigroup
New York
$40K +$49.1K +4,942 +709%
Legal & General Group
69
Legal & General Group
United Kingdom
$25K +$4.23K +426 +14%
TRCT
70
Tower Research Capital (TRC)
New York
$20K +$28.8K +2,899 New
Ohio Public Employees Retirement System (OPERS)
71
Ohio Public Employees Retirement System (OPERS)
Ohio
$20K +$28.8K +2,900 New
Bank of Montreal
72
Bank of Montreal
Ontario, Canada
$19K +$7.19K +724 +35%
BNP Paribas Financial Markets
73
BNP Paribas Financial Markets
France
$14.7K +$1.72K +173 +9%
PCM
74
Prelude Capital Management
New York
$11K +$15.9K +1,600 New
MAM
75
Meeder Asset Management
Ohio
$9K -$22.2K -2,240 -65%
1 2
3
4

PTGX Hedge Fund Activity: Q4 2019 in Review

81 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2019, worth a combined $164M — down 28% from $228M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new PTGX positions and 13 closed out — a net gain of 5 holders — while 34 added to existing stakes and 15 trimmed.

The largest buyer was RTW Investments, adding an estimated $16.9M. The largest seller was VHCP Management III, cutting an estimated $9.85M.

  • 81 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2019, up from 76 in Q3 2019.
  • Funds reported $164M of Protagonist Therapeutics stock for Q4 2019, down 28% quarter-over-quarter.
  • 18 funds opened new Protagonist Therapeutics positions in Q4 2019 and 13 closed out, a net change of +5 holders.
  • The largest Protagonist Therapeutics buyer in Q4 2019 was RTW Investments, an estimated $16.9M added.
  • The largest Protagonist Therapeutics seller in Q4 2019 was VHCP Management III, an estimated $9.85M sold.

Based on aggregated 13F filings for Q4 2019.